Markets:

Overview

News

Currencies

International

Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.080 +0.010 (+0.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

3 Unprofitable Stocks Walking a Fine Line

May 02, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

May 01, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

April 30, 2025

More than half say genetic testing for mental health medications could reduce concerns

From Myriad Genetics, Inc.

Via GlobeNewswire

Analyst Expectations For Myriad Genetics's Future ↗

March 03, 2025

Via Benzinga

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

April 29, 2025

Management will participate in two upcoming investor healthcare conferences

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

April 25, 2025

Podium presentation showcases the clinical application of Precise™ MRD

From Myriad Genetics, Inc.

Via GlobeNewswire

3 Healthcare Stocks That Concern Us

April 25, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

April 21, 2025

Study published in the Journal of Clinical Psychopharmacology

From Myriad Genetics, Inc.

Via GlobeNewswire

Demystifying Myriad Genetics: Insights From 10 Analyst Reviews ↗

April 17, 2025

Via Benzinga

Myriad Genetics Announces Inducement Awards

April 08, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

April 07, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

10 Analysts Assess Myriad Genetics: What You Need To Know ↗

April 01, 2025

Via Benzinga

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 01, 2025

Via Benzinga

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

March 20, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

March 17, 2025

Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 per share. This might have investors contemplating their next move.

Via StockStory

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗

March 12, 2025

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Via Benzinga

Why Are Myriad Genetics (MYGN) Shares Soaring Today

March 12, 2025

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook...

Via StockStory

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

March 12, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

March 04, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

Via StockStory

Topics Artificial Intelligence

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

February 27, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO ↗

February 25, 2025

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO.

Via Benzinga

Why Myriad Genetics (MYGN) Shares Are Plunging Today

February 25, 2025

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025...

Via StockStory

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

February 25, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

February 25, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops

February 24, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue...

Via StockStory

Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth

February 24, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Announces Senior Leadership Transition

February 24, 2025

Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.